Long-term Maintenance of ≥50% and ≥75% Migraine Response With Eptinezumab in Patients With High-frequency Episodic Migraine and Chronic Migraine and 2–4 Prior Migraine Preventive Treatment Failures (P12-12.005)
This post hoc analysis of the DELIVER trial evaluated sustained ≥50% or ≥75% migraine responses over 72 weeks of eptinezumab treatment in patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM).
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Scott N. Grossman (ORCID: https://orcid.org/0000-0001-7033-5226)
- Nitin Kapur (ORCID: https://orcid.org/0000-0002-8423-0596)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Susanne F. Awad (ORCID: https://orcid.org/0000-0002-5060-7404)
- Seema Soni-Brahmbhatt (ORCID: https://orcid.org/0000-0002-4714-6010)
- Messoud Ashina
Institutions
- University of Copenhagen (DK)
- Albert Einstein College of Medicine (US)
- Lundbeck (Denmark) (DK)
- Georgetown University (US)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Lundbeck (Germany) (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211318
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00